These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 12694817)

  • 1. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma.
    Rosser CJ; Reyes AO; Vakar-Lopez F; Levy LB; Kuban DA; Hoover DC; Lee AK; Pisters LL
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):1-6. PubMed ID: 12694817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity.
    Grossfeld GD; Olumi AF; Connolly JA; Chew K; Gibney J; Bhargava V; Waldman FM; Carroll PR
    J Urol; 1998 May; 159(5):1437-43. PubMed ID: 9554329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
    Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
    Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
    Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
    Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
    Moul JW
    Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
    Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
    Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment results of adjuvant radiotherapy and salvage radiotherapy after radical prostatectomy for prostate cancer.
    Wadasaki K; Kaneyasu Y; Kenjo M; Matsuura K; Murakami Y; Hashimoto Y; Ito K; Kiriu H; Ito A
    Int J Clin Oncol; 2007 Feb; 12(1):37-41. PubMed ID: 17380439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
    Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K
    Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
    MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
    Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.
    Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Moul JW
    J Urol; 1996 Oct; 156(4):1511-6. PubMed ID: 8808919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.
    Leonardo C; Simone G; Papalia R; Franco G; Guaglianone S; Gallucci M
    Int J Urol; 2009 Jun; 16(6):584-6. PubMed ID: 19453762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage prostatectomy in patients who have failed radiation therapy or cryotherapy as primary treatment for prostate cancer.
    Chen BT; Wood DP
    Urology; 2003 Dec; 62 Suppl 1():69-78. PubMed ID: 14747044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage radical prostatectomy for radio-recurrent prostate cancer: is this a viable option?
    Steinberg GD
    Curr Opin Urol; 2000 May; 10(3):229-32. PubMed ID: 10858902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic markers in clinically localized prostate cancer.
    Pettaway CA
    Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer.
    Mizera-Nyczak E; Dyszkiewicz W; Heider KH; Zeromski J
    Tumour Biol; 2001; 22(1):45-53. PubMed ID: 11054026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes.
    Do T; Dave G; Parker R; Kagan AR
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1220-5. PubMed ID: 11483332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
    Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
    Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.